Literature DB >> 15343199

Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children.

David M Burger1, Alina S Bergshoeff, Ronald De Groot, Diana Gibb, Sarah Walker, Jean-Marc Tréluyer, Richard M W Hoetelmans.   

Abstract

Differences in virologic response were compared in 32 HIV-infected children with a nelfinavir trough concentration either below (n=7) or above (n=25) 0.8 mg/L. Virologic response at week 48 was observed in 29% of children with subtherapeutic nelfinavir troughs versus 80% in children with therapeutic nelfinavir troughs (P=.02).

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15343199     DOI： 10.1016/j.jpeds.2004.04.048

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


  7 in total

Review 1.  Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.

Authors:  Michael N Neely; Natella Y Rakhmanina
Journal:  Clin Pharmacokinet       Date:  2011-03       Impact factor: 6.447

2.  Nelfinavir and its active metabolite, hydroxy-t-butylamidenelfinavir (M8), are transferred in small quantities to breast milk and do not reach biologically significant concentrations in breast-feeding infants whose mothers are taking nelfinavir.

Authors:  Paul J Weidle; Clement Zeh; Amy Martin; Richard Lando; Frank Angira; Joseph Osoga; Paul Ogindo; Sonali Girde; Timothy D Minniear; Timothy K Thomas
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

Review 3.  Practical guidelines to interpret plasma concentrations of antiretroviral drugs.

Authors:  Bregt S Kappelhoff; Kristel M L Crommentuyn; Monique M R de Maat; Jan W Mulder; Alwin D R Huitema; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 4.  Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges.

Authors:  B Ryan Phelps; Natella Rakhmanina
Journal:  Paediatr Drugs       Date:  2011-06-01       Impact factor: 3.022

5.  Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples.

Authors:  Déborah Hirt; Saïk Urien; Vincent Jullien; Ghislaine Firtion; Hélène Chappuy; Elisabeth Rey; Gérard Pons; Laurent Mandelbrot; Jean-Marc Treluyer
Journal:  Br J Clin Pharmacol       Date:  2007-09-24       Impact factor: 4.335

6.  Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children.

Authors:  Déborah Hirt; Saïk Urien; Vincent Jullien; Ghislaine Firtion; Elisabeth Rey; Gérard Pons; Stéphane Blanche; Jean-Marc Treluyer
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

7.  Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation.

Authors:  Gerben van 't Klooster; Eva Hoeben; Herman Borghys; Adriana Looszova; Marie-Paule Bouche; Frans van Velsen; Lieven Baert
Journal:  Antimicrob Agents Chemother       Date:  2010-02-16       Impact factor: 5.191
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.